Table of contents:
- N vaccineovel coronavirus still being developed
- 1,012,350
- 820,356
- 28,468
- Constraints in developing vaccines novel coronavirus
As a result of the plague Novel coronavirus which attacked China and several other countries, more than 800 people were infected and 26 people were reported dead. Viral and bacterial infections can generally be prevented through vaccines. However, there are a number of obstacles that make the N vaccine ovel coronavirus until now not available.
If used effectively, vaccines can not only prevent the spread of dangerous diseases, but also make them less deadly. So, what are the obstacles in the development of this viral vaccine?
N vaccine ovel coronavirus still being developed
Novel coronavirus are part of the family coronavirus which infects the respiratory tract. This group of viruses can cause a variety of illnesses, from the common cold and flu to more severe illnesses such as pneumonia and bronchitis.
Coronavirus is also known to cause outbreaks Severe Acute Respiratory Syndrome (SARS) in 2002 and Middle-East Respiratory Syndrome (MERS) in 2013 ago. Both infected thousands and resulted in hundreds of deaths.
Before novel coronavirus appears, many researchers have tried to develop vaccines for SARS and MERS. A number of researchers in 2003 successfully tested the SARS vaccine against humans, but vaccine development was discontinued because the SARS outbreak at that time had ended.
Vaccine development for MERS is also constrained by time, cost, and risk of side effects. According to W. Ian Lipkin, professor at the Mailman School of Public Health, USA, the risk of a person getting side effects of the MERS vaccine is greater than the risk of being infected with the virus.
1,012,350
Confirmed820,356
Recovered28,468
DeathDistribution MapHowever, research on the SARS and MERS vaccines a few years ago is now a provision for many scientists to develop vaccines novel coronavirus . The reason is, the three viruses are said to have many similarities.
A group of researchers in Texas, New York and China are still working to identify the genetic code for the virus, which has been named 2019-nCoV. The good news is, this process no longer takes months as in the previous SARS case, but only a few weeks.
Constraints in developing vaccines novel coronavirus
The barriers to developing the 2019-nCoV vaccine are basically the same as those of other vaccines. There are two main factors at play, namely scientific factors and lack of funding.
Scientific factors include the characteristics of the germs studied and the risk of vaccine side effects. Meanwhile, a lack of funding can hinder the development and distribution of vaccines to certain areas, even if these areas are considered vulnerable.
A study contained in Journal of Medical Microbiology provides an overview of some of the common obstacles to vaccine development. The following include:
- Inadequate preclinical data and a lack of information on community immunity may derail later clinical trials.
- Lack of information on exposure to infection in potential vaccine recipients.
- Vaccines will be used in groups of people whose immune systems are not very responsive.
- Variations in germs make researchers always have to update vaccine formulations.
- The high cost of developing vaccines means that potential products are ultimately neglected.
- Lack of access to vaccines in poorer countries.
Vaccine novel coronavirus it is still in the development stage. However, this lengthy process will yield commensurate results in the future. While waiting for the vaccine to be made, the best step that can be taken at this time is to take preventive measures.
